×

Biotech and Pharmaceuticals Medicine

  • Oct 10- Eli Lilly and Co said its drug to treat non-small cell lung cancer failed to meet the main goal of improving overall survival in patients in a late-stage trial, sending its shares down about 3 percent. The U.S. Food and Drug Administration had rejected Lilly's rheumatoid arthritis drug in April, while its Alzheimer's treatment failed a key trial in...

  • Oct 10- Eli Lilly and Co said on Tuesday its drug to treat non-small cell lung cancer failed to meet the main goal of improving overall survival in patients in a late-stage study. Lilly's shares fell 2.4 percent to $85.00 in light premarket trading. Last month, the U.S. Food and Drug Administration approved Verzenio to treat advanced breast cancer that has...

  • Oct 10- Eli Lilly and Co said on Tuesday its drug to treat non-small cell lung cancer failed to meet the main goal of improving overall survival in patients in a late-stage study.

  • Mike Clayman, CEO, Flexion Therapeutics

    When asked if Flexion would look to other applications for its new non-opioid drug, its CEO said, "We're absolutely thinking about it."

  • *Drug to be priced at about $500 per shot. Oct 6- Flexion Therapeutics Inc said its injectable drug to treat osteoarthritis-related knee pain was approved by the U.S. Food and Drug Administration, sending the drug developer's shares soaring to a record high in regular trading on Friday. The osteoarthritis drug, Zilretta, which will treat moderate-to-severe knee...

  • Oct 6- Flexion Therapeutics Inc said on Friday the U.S. Food and Drug Administration approved its injectable drug, Zilretta, to treat moderate-to-severe osteoarthritis-related knee pain, sending its shares soaring 18 percent. The drug would be priced at about $500 for a single injection, Flexion's CEO Mike Clayman told Reuters, adding that it would be launched...

  • Oct 6- Flexion Therapeutics Inc said on Friday the U.S. Food and Drug Administration approved its drug, Zilretta, to treat moderate-to-severe osteoarthritis-related knee pain. The approval came at a time when federal authorities in the United States are implementing a slew of measures to cut down the supply of opioid painkillers amid their continuous abuse,...

  • Regeneron shares pop on cholesterol drug approval

    Regeneron shares are popping intraday after news of their cholesterol drug receives approval.

  • Oct 5- Animas Corp, Johnson& Johnson's diabetes care unit, said it intends to exit the insulin pump business due to increased competition and has selected rival Medtronic Plc as its partner for the device. Animas said it has discontinued the sale of all Animas Vibe and OneTouch Ping insulin pumps in the United States and Canada, effective immediately.

  • The coronal view of a human brain of a patient suffering from Parkinson's disease

    This pacemaker for the brain can be used to treat symptoms of neurological disorders, like Parkinson’s disease.

  • Oct 5- Animas Corp, Johnson& Johnson's diabetes care unit, said it intends to exit the insulin pump business and has selected Medtronic Plc as its partner for patients on insulin pumps. Patients using an Animas insulin pump will be offered the option to transfer to a Medtronic pump, the company said on Thursday. Nearly 90,000 patients use company's pumps and...

  • Peter Thiel and Sean Parker are financing a secretive cancer-fighting start-up, source says

    A start-up called 3T Biosciences n the T-cell therapy space quietly raised more than $12 million from high-profile investors, a source says.

  • CHICAGO, Oct 4- A DNA-based Zika vaccine from Inovio Pharmaceuticals Inc and South Korea's GeneOne Life Science Inc induced anti-Zika immune responses in an early stage human trial, U.S. researchers reported on Wednesday. Unlike conventional vaccines, which often use inactivated or killed versions of a virus, the Inovio-GeneOne shot is a synthetic vaccine...

  • Mylan headquarters Canonsburg, Pennsylvania

    CNBC's Meg Tirrell speaks with David Maris, Wells Fargo Securities senior analyst, about the generic competition between Mylan and Teva after Mylan gets approval for a generic MS drug.

  • FDA approves Mylan generic MS treatment

    CNBC's Meg Tirrell reports on Mylan soaring after FDA approves their generic multiple sclerosis treatment as Teva shares sinks. The “Fast Money Halftime Report” traders weigh in.

  • Oct 3- Mylan NV said the U.S. Food and Drug Administration has approved two doses of its generic version of Teva's Copaxone used to treat patients with relapsing forms of multiple sclerosis. Shipping of the Glatiramer Acetate 40 mg/mL for 3- times-a-week injection and 20 mg/mL for once-daily injection will begin imminently, the company said on Tuesday.

  • Allergan's unusual patent agreement

    CNBC's Meg Tirrell reports on senators commenting on Allergan's patent agreement with the Saint Regis Mohawk Tribe.

  • Retiring baby boomers will more than double Medicare and Medicaid costs by 2020, according to industry data.

    As boomers retire, the health-care industry must devise solutions that strive for affordability and ways to lower costs behind the scenes.

  • LONDON, Oct 3- A seasonal flu vaccine that would be the first in the world to fight all types of the virus is to be tested in a two-year clinical trial involving more than 2,000 patients by researchers in Oxford. The so-called universal vaccine was developed by Oxford University's Jenner Institute and Vaccitech, a spin-out biotech company founded by Jenner...

  • Training cells to fight cancer

    In today’s Modern Medicine series, CNBC’s Meg Tirrell brings us the story of a little girl whose life was saved by a different kind of cancer treatment.